CD8A and neoplasm: We selected CCL19 as APC binding molecule for further characterization based on its ability to increase the immunogenicity of the fused neoepitopes inducing a balanced neoepitope-specific CD4+ and CD8+ T-cell responses and leading to complete tumor rejection in a prophylactic setup.